Last reviewed · How we verify
NCT03489187: VIVID-1
Visualase Visualization Database (VIVID-1)
trial testing Visualase Thermal Therapy System in Epilepsy in 183 participants. Completed in 29 April 2022.
29 April 2022
Quick facts
| Lead sponsor | MedtronicNeuro |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 183 |
| Start date | 5 March 2018 |
| Primary completion | 29 April 2022 |
| Estimated completion | 29 April 2022 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Visualase Thermal Therapy System
Conditions studied
Sponsor
MedtronicNeuro — full company profile →
Who can join
Eligibility, any sex, with Epilepsy or Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the VIVID-1 data collection study is to establish a database of clinical images and associated technical files from commercial cases using the Visualase Thermal Therapy System (VTTS). All data collected will be de-identified. No safety or effectiveness assessments will be completed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03489187
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Visualase Thermal Therapy System
Trials testing the same drug.
- NCT01377753 — MR Image Guided Therapy in Prostate Cancer · Phase 2 · completed
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other MedtronicNeuro trials
Trials by the same sponsor.
- NCT05775510 — Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chro · terminated
- NCT05226286 — Evaluation of Implantable Tibial Neuromodulation Pivotal Study (TITAN 2) · NA · completed
- NCT05200923 — Pelvic Health Electrically Evoked Recording (PEER) 2 Study · NA · recruiting
- NCT05177354 — Medtronic Closed-Loop Spinal Cord Stimulation System · NA · completed
- NCT07106242 — Adaptive Deep Brain Stimulation (aDBS) Study (Early Adapter) Part II · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03489187 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MedtronicNeuro
- Last refreshed: 4 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03489187.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing